High hematocrit on TRT: the number that ends therapy, and the bad advice that follows

Why testosterone thickens your blood

The mechanism is well mapped and it has two engines. Testosterone raises erythropoietin (EPO), the kidney hormone that tells the marrow to build red cells, and it recalibrates the EPO/hemoglobin set point: the body defends a higher hemoglobin level as if it were normal. On top of that, testosterone stimulates the marrow directly, independent of EPO. A 2014 study in healthy men, Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin, measured both effects and found something else that matters later on this page: alongside the 7% rise in hemoglobin, ferritin and hepcidin fell.

Hepcidin is the body's iron gatekeeper. More red-cell production means more erythroferrone from the marrow, which suppresses hepcidin, which opens the gates: stored iron (ferritin) pours out to build hemoglobin, and less iron gets stored. So the same therapy that raises your hematocrit quietly drains your iron reserves, before you have donated a single unit. That is not a side-note; it is why the phlebotomy conversation and the ferritin conversation are one conversation.

The numbers the guidelines actually say

The Endocrine Society's 2018 clinical practice guideline is the one most US prescribers follow, and its instruction is specific: check hematocrit at baseline, three to six months after starting, and then annually. If hematocrit exceeds 54%, stop therapy until it decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate at a reduced dose. The European Association of Urology uses the same 54% line and adds that dose adjustment and/or venesection (500 mL) should be considered, repeating if necessary.

Two honest caveats about that 54%. First, the EAU traces it to a Framingham Heart Study analysis of hematocrit and cardiovascular mortality, in a general population with plenty of smokers, not in men on testosterone; the threshold is convention more than measured TRT risk. Second, and this is the part that helps you: the guideline's "stop and evaluate" step names sleep apnea and hypoxia for a reason. Untreated sleep apnea and smoking are independent erythrocytosis drivers, and a man on TRT with an unexplained hematocrit climb deserves a sleep study and an honest look at the other drivers before anyone reaches for the blood bag or the "you're off testosterone" stamp.

One lab-literacy note while you're here: hematocrit is a ratio, red-cell volume over total blood volume, and it moves with hydration. A dehydrated draw reads falsely high. If your number jumped, retest well-hydrated before making decisions, and if your lab reports a hemoglobin of 18 g/dL or a hematocrit at or above 54%, that is the guideline threshold to take seriously with your prescriber, not something to argue with on a forum.

The bad advice hall of fame

Six things men on TRT are told constantly, checked against what the sources actually say.

What actually moves the number

In rough order of evidence strength, the levers that work:

• Fix the other drivers first. Treat sleep apnea, stop smoking, retest hydrated. The guideline itself says evaluate for hypoxia before anything else.
• Change how the testosterone is delivered. Injectable esters cause the most erythrocytosis because they spike; transdermal gels, nasal, and buccal routes are associated with far less of it. If injections are staying, splitting the weekly dose into more frequent shots flattens the peaks, and a trial of the subcutaneous testosterone enanthate autoinjector (Xyosted) found hematocrit increases about 41% lower than the same weekly dose given intramuscularly, roughly two hematocrit points at similar testosterone levels.
• Phlebotomy or donation, when the number says so. This is the lever with the most direct effect: removing red cells removes red cells. Whole-blood donation is allowed every 8 weeks and double-red (Power Red) every 16 weeks by US collection rules. Whether you need it at a hematocrit of 51 versus 54 is genuinely debated and genuinely individual; at 54% it is guideline territory, and at 60% it is not a debate, it is an appointment this week. The Canadian donor data is the honest framing: donation lowers the number, and TRT pushes it back up, so for some men this is a maintenance rhythm, not a one-time fix.
• Blood-pressure drugs your prescriber may choose. ARBs like telmisartan and losartan have literature and heavy community reporting behind modest hematocrit-lowering effects (angiotensin II feeds EPO production in the kidney), and telmisartan is already a favorite on this site for men with both ED and hypertension. The evidence for hematocrit specifically is thin, so this is a prescriber conversation, not a self-prescription.
• Aspirin, with clear eyes. Low-dose aspirin does not lower hematocrit at all. What it does is inhibit platelet aggregation, which is why some clinicians add 81 mg when hemoglobin climbs, as clot-event insurance. If someone sells you aspirin as the fix for thick blood, they are selling you the wrong mechanism.
• Rusfertide, the one to watch. On August 28, 2026 the FDA approved Mimrylo (rusfertide), a first-in-class synthetic hepcidin mimetic, for erythrocytosis in polycythemia vera. In the phase 3 VERIFY trial, 76.9% of rusfertide patients needed no phlebotomy across 32 weeks versus 32.9% on placebo. It is approved for PV, a different disease, and not for testosterone-induced erythrocytosis. But it is proof the hepcidin pathway is druggable, and it is the closest thing to a real fix on the horizon for the TRT version of this problem.

The ferritin crash nobody warns you about

Here is the trap the donation debate misses. TRT already suppresses hepcidin and drains ferritin, per the mechanism above. Repeated phlebotomy then removes iron directly, because every unit of blood carries roughly 200-250 mg of it out the door. Stack the two and you get the profile legions of TRT men report and almost nobody tests for: hematocrit controlled, hemoglobin fine, ferritin on the floor, and the man feels drained, restless, and flat. Community reports converge on ferritin below roughly 30 ng/mL as the "feel like crap" zone, with 50-70 restoring most men, though those thresholds are forum-observed, not guideline-grade.

The literacy move is simple: if you are donating or getting phlebotomized on TRT, ask for ferritin alongside the CBC, every time. If it is low, iron repletion is a clinician conversation, and the one thing worth saying to that clinician is that men with C282Y hereditary hemochromatosis must not load iron blindly; an HFE test settles the question cheaply. There is an elaborate community protocol circulating (the "Vorck ferritin protocol," short bursts of high-dose non-heme iron aimed at spiking hepcidin so the body re-stores its own recycled iron rather than absorbing the supplement) with enthusiastic anecdotal reports and no controlled trials behind it. We're not going to print dosing steps for an unvalidated iron-loading scheme; iron overload is a real harm. What we will say: it exists, men report it works, it has not been tested the way a treatment should be, and if you pursue it, do it with a clinician who knows your ferritin trajectory and your hemochromatosis status.

When it stops being a labs conversation

Most elevated hematocrit is asymptomatic and managed on a schedule. The symptoms that change the urgency: a flushed, ruddy complexion, headaches, blurred vision, itching after hot showers, shortness of breath, and the clot signs that send you in immediately, chest pain, one-sided weakness, trouble speaking, a swollen painful calf. A hematocrit approaching 60% with symptoms is same-day medical territory. That is the one point in this entire debate where both crowds agree.

And the meta-lesson of this page applies to the whole TRT project: the difference between safe therapy and drift is monitoring. If your program checks hematocrit at baseline, at three to six months, and annually, and has an actual plan for what happens when it climbs, you are in the supervised channel this site keeps pointing toward. If your hematocrit has never been mentioned to you, that is the finding, and it's worth more than the number itself.

The bottom line

Testosterone raises red cells through EPO and direct marrow stimulation, and suppresses hepcidin while it does it, which is why hematocrit climbs and ferritin falls together. The guideline number is 54%, not 45. Lowering the dose fixes it for well under 1% of men. Donation works, and works repeatedly, because the driver is continuous; the studies "proving" it fails are being misread. Altitude and athlete comparisons don't survive their own data. Change the delivery route, fix sleep apnea, retest hydrated, ask for ferritin every draw, and take the rusfertide approval as the sign it is: this problem is finally getting real pharmacology. Read the CBC in the context of your full lab panel, keep the monitoring honest per what safe TRT requires, and if your current prescriber has no answer for a climbing hematocrit, that is what the clinic directory is for.

Common questions